The Business Times
business-time-50
SUBSCRIBERS

Singapore biotech startup Nanyang Biologics bets on AI drug discovery platform to unlock revenue

After investing six years in R&D, the firm is heading to Nasdaq via a US$1.5 billion Spac deal as it lands its first client

Summarise
google-preferred-sourceAdd BT as a preferred source
Tessa Oh

Tessa Oh

Published Wed, Oct 22, 2025 · 09:33 AM
阅读简体中文版 (beta)
    • Dr Roland Ong, founder and chairman of Nanyang Biologics, says: “Biotech, AI and drug discovery are a long-term R&D process and continuous funding is required.”
    • Dr Roland Ong, founder and chairman of Nanyang Biologics, says: “Biotech, AI and drug discovery are a long-term R&D process and continuous funding is required.” PHOTO: TAY CHU YI, BT

    DeeperDive is a beta AI feature. Refer to full articles for the facts.

    [SINGAPORE] Drug development typically takes six to 10 years just to identify a viable molecule, but Singapore biotech firm Nanyang Biologics reckons it can do the job in six minutes.

    Originally founded as a biopharma startup to develop cancer and cardiovascular therapies, the company simultaneously spent six years building an artificial intelligence (AI) platform to accelerate its own drug discovery work.

    Now it has commercialised that technology as NYB.AI, positioning it as a tool for pharmaceutical and health supplement manufacturers looking to slash costs and timelines.

    Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.

    Singapore SMEsBiotechStartupArtificial Intelligence

    Copyright SPH Media. All rights reserved.

    Reuse this contentFeedback

    TRENDING NOW

    In this economy, the smartest bets might no longer be sitting an ocean away, but are waiting right here at home.

    ‘Boring’ is the new black: The stars are aligning for a Singapore stock market revival

    Sales have rebounded in March after the year-end lull and seasonal Chinese New Year pullback.

    Near sell-out launches in March boost developer sales to 1,300 units after four slow months

    US President Donald Trump (left) with Chinese President Xi Jinping at a bilateral meeting on the sidelines of the Apec summit in Busan last October.

    China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result

    Lim's pay package includes about S$3.6 million as salary and around S$3.9 million as bonus, indicates the company's annual report.

    Genting Singapore’s Lim Kok Thay receives S$7.5 million pay package for FY2025

    Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
    Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
    View More